Phase II study of pembrolizumab in advanced, unresectable hepatocellular carcinoma.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.4086
Abstract: 4086Background: Recently, checkpoint inhibitors have shown modest activity in patients (pts) with advanced, unresectable hepatocellular carcinoma (HCC). In multicenter trials with nivolumab and pem... read more here.
Keywords: hepatocellular carcinoma; unresectable hepatocellular; advanced unresectable; study pembrolizumab ... See more keywords
Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) one to three from KEYNOTE-199.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e17584
Abstract: e17584Background: Pembrolizumab monotherapy has shown antitumor activity and acceptable safety in patients with mCRPC previously treated with a next-generation hormone agent (NHA) and docetaxel. Pr... read more here.
Keywords: docetaxel pretreated; pretreated patients; patients metastatic; pembrolizumab docetaxel ... See more keywords
Phase II study of pembrolizumab plus SurVaxM for glioblastoma at first recurrence.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.tps2581
Abstract: TPS2581Background: Glioblastoma is the most common primary malignant brain tumor with median survival of approximately 15-16 months. Following first recurrence, progression free survival at six mon... read more here.
Keywords: first recurrence; glioblastoma; pembrolizumab plus; study pembrolizumab ... See more keywords
Phase II study of pembrolizumab plus olaparib in the treatment of patients with advanced cholangiocarcinoma.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.tps4659
Abstract: TPS4659Background: Lack of an effective second-line treatment of patients (pts) with advanced cholangiocarcinoma (CC) necessitates the development of new therapies. Preclinical studies suggest CC s... read more here.
Keywords: treatment patients; pembrolizumab plus; advanced cholangiocarcinoma; study pembrolizumab ... See more keywords
Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.3500
Abstract: 3500Background: In the phase III, randomized open-label KEYNOTE-177 (NCT02563002) study 1L pembrolizumab (pembro) versus chemotherapy (chemo) provided superior progression-free survival (PFS) at se... read more here.
Keywords: versus chemotherapy; phase iii; study pembrolizumab;
Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Interim analysis.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.3_suppl.77
Abstract: 77Background: MSS mCRC rarely responds to pembrolizumab monotherapy, but capecitabine and bevacizumab may induce immune-stimulatory effects. This study evaluates the safety, tolerability and prelim... read more here.
Keywords: study pembrolizumab; mcrc; mss; capecitabine bevacizumab ... See more keywords